Logo image of BU.CA

BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

TSX:BU - Toronto Stock Exchange - CA1208311029 - Common Stock - Currency: CAD

0.105  -0.01 (-4.55%)

Fundamental Rating

2

Taking everything into account, BU scores 2 out of 10 in our fundamental rating. BU was compared to 30 industry peers in the Chemicals industry. Both the profitability and financial health of BU have multiple concerns. BU is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BU has reported negative net income.
In the past year BU has reported a negative cash flow from operations.
BU had negative earnings in each of the past 5 years.
In the past 5 years BU always reported negative operating cash flow.
BU.CA Yearly Net Income VS EBIT VS OCF VS FCFBU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

BU has a Return On Assets of -94.65%. This is in the lower half of the industry: BU underperforms 76.67% of its industry peers.
Industry RankSector Rank
ROA -94.65%
ROE N/A
ROIC N/A
ROA(3y)-116.26%
ROA(5y)-73.05%
ROE(3y)-264.46%
ROE(5y)-163.05%
ROIC(3y)N/A
ROIC(5y)N/A
BU.CA Yearly ROA, ROE, ROICBU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

1.3 Margins

BU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BU.CA Yearly Profit, Operating, Gross MarginsBU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
BU has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BU has been increased compared to 5 years ago.
The debt/assets ratio for BU has been reduced compared to a year ago.
BU.CA Yearly Shares OutstandingBU.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BU.CA Yearly Total Debt VS Total AssetsBU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -24.28, we must say that BU is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -24.28, BU is doing worse than 73.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.28
ROIC/WACCN/A
WACC7.06%
BU.CA Yearly LT Debt VS Equity VS FCFBU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

BU has a Current Ratio of 0.41. This is a bad value and indicates that BU is not financially healthy enough and could expect problems in meeting its short term obligations.
BU has a Current ratio of 0.41. This is in the lower half of the industry: BU underperforms 73.33% of its industry peers.
BU has a Quick Ratio of 0.41. This is a bad value and indicates that BU is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.33, BU is doing worse than 60.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.33
BU.CA Yearly Current Assets VS Current LiabilitesBU.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

8

3. Growth

3.1 Past

BU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.29%, which is quite impressive.
The Revenue has grown by 88.11% in the past year. This is a very strong growth!
BU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.75% yearly.
EPS 1Y (TTM)27.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.16%
Revenue 1Y (TTM)88.11%
Revenue growth 3Y-10.82%
Revenue growth 5Y35.75%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BU will show a very strong growth in Earnings Per Share. The EPS will grow by 52.09% on average per year.
Based on estimates for the next years, BU will show a very strong growth in Revenue. The Revenue will grow by 128.44% on average per year.
EPS Next Y5.34%
EPS Next 2Y52.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.6%
Revenue Next 2Y128.44%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BU.CA Yearly Revenue VS EstimatesBU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
BU.CA Yearly EPS VS EstimatesBU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

BU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 6.16, the valuation of BU can be described as very cheap.
BU's Price/Forward Earnings ratio is rather cheap when compared to the industry. BU is cheaper than 96.67% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.27, BU is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 6.16
BU.CA Price Earnings VS Forward Price EarningsBU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BU.CA Per share dataBU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04

4.3 Compensation for Growth

BU's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BU's earnings are expected to grow with 52.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.09%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURCON NUTRASCIENCE CORP

TSX:BU (6/6/2025, 7:00:00 PM)

0.105

-0.01 (-4.55%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-14 2025-02-14/amc
Earnings (Next)07-01 2025-07-01/amc
Inst Owners7.87%
Inst Owner ChangeN/A
Ins Owners28.31%
Ins Owner ChangeN/A
Market Cap26.64M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.79%
Min EPS beat(2)-94.17%
Max EPS beat(2)-17.4%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-90.94%
Min Revenue beat(2)-93.53%
Max Revenue beat(2)-88.35%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)100%
EPS NY rev (1m)0%
EPS NY rev (3m)-51.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.16
P/S 78.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)0.02
Fwd EY16.22%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.26%
ROA(5y)-73.05%
ROE(3y)-264.46%
ROE(5y)-163.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.33%
Cap/Sales 71.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.33
Altman-Z -24.28
F-Score3
WACC7.06%
ROIC/WACCN/A
Cap/Depr(3y)75.59%
Cap/Depr(5y)243.69%
Cap/Sales(3y)66.11%
Cap/Sales(5y)174.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.16%
EPS Next Y5.34%
EPS Next 2Y52.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)88.11%
Revenue growth 3Y-10.82%
Revenue growth 5Y35.75%
Sales Q2Q%N/A
Revenue Next Year-36.6%
Revenue Next 2Y128.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.67%
OCF growth 3YN/A
OCF growth 5YN/A